Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 14 of 15

 
 

Avidity Biosciences (NASDAQ:RNA)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$63.22 (26.5% Upside)

About Avidity Biosciences

Avidity Biosciences logoAvidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/13/2024Chardan CapitalReiterated RatingBuy ➝ Buy$65.00 ➝ $65.00
11/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
10/31/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
10/30/2024Chardan CapitalBoost Price TargetBuy ➝ Buy$60.00 ➝ $65.00
10/21/2024TD CowenBoost Price TargetBuy ➝ Buy$56.00 ➝ $78.00
9/24/2024The Goldman Sachs GroupInitiated CoverageBuy$59.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$96.00 ➝ $96.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$96.00 ➝ $96.00
8/28/2024BarclaysInitiated CoverageOverweight$63.00
8/26/2024Evercore ISILower Price TargetOutperform ➝ Outperform$54.00 ➝ $53.00
 

Bill Gates’s Next Big AI Bet: Stargate (Ad)

In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate